Device Trial Radar · NCT07084545
Evaluation of Cataract Surgery Outcomes in Patients With Prior Laser Vision Correction Implanted With the CT LUCIA Lens
Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 2025
Primary completion
Jul 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- Carl Zeiss Meditec AGNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 24, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, Phase IV, post-approval observational study evaluating postoperative outcomes in patients with a history of myopic corneal laser vision correction (LVC) undergoing bilateral cataract surgery with implantation of the CT LUCIA 621P intraocular lens (IOL). Up to 30 subjects (60 eyes) will be enrolled across up to three U.S. investigational sites. The study will assess visual and refractive outcomes, including biometry, manifest refraction, and patient-reported visual function over a 3-month follow-up period.
Conditions
- Postoperative Visual Outcomes Following Cataract Surgery in Patients With Prior Myopic Corneal Laser Vision Correction
Interventions
CT LUCIA 621P Intraocular Lens ImplantationDevice
The intervention consists of bilateral implantation of the CT LUCIA 621P intraocular lens (IOL) during routine cataract surgery in patients with a history of myopic corneal laser vision correction. The CT LUCIA 621P IOL is an approved, single-piece, hydrophobic acrylic lens designed to provide improved visual quality and refractive stability. Implantation is performed following each investigator's standard surgical procedures, including preoperative preparation, operative technique, and postoperative care. IOL power calculation uses the ZEISS Cataract Workflow platform with the VERACITY system and Barrett True-K with TK formula, incorporating the VERION Optical Coherence (VOC) technology.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Prediction Error (PE)Time frame: 3 months postoperatively
- Median Prediction Error (PE)Time frame: 3 months postoperatively
- Absolute Prediction Error (PE)Time frame: 3 months postoperatively
3 more outcomes with a free account
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Berkeley Eye Center
Sugar Land, Texas · Recruiting
Piedmont Eye Center
Lynchburg, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.